According to the announcement from WuXi AppTec-B (02617), the company has been selected to be included in the Hang Seng Index series components, effective from September 8, 2025, based on the quarterly review results announced by Hang Seng Indexes Company Limited on August 22, 2025. The indices include but are not limited to the following:
<ol>
<li>
Hang Seng Composite Index;
</li>
<li>
Hang Seng Composite Industry Index - Healthcare;
</li>
<li>
Hang Seng Composite Small and Mid-Cap Index;
</li>
<li>
Hang Seng Composite Small Cap Index;
</li>
<li>
Hang Seng Healthcare Index;
</li>
<li>
Hang Seng Innovative Drug Index;
</li>
<li>
Hang Seng Stock Connect Innovative Drug Index;
</li>
<li>
Hang Seng Stock Connect Innovative Drug Select Index; and
</li>
<li>
Hang Seng Stock Connect Pharmaceuticals and Biotechnology (Investable) Index.
</li>
</ol>
The announcement stated that the inclusion of the company in the Hang Seng Composite Index and the above indices reflects an increase in investor recognition

02617

TRANSTHERA-B announced that it will be included in the Hang Seng Index series constituents starting from September 8, 2025, including the Hang Seng Composite Index and several healthcare-related indices. This decision reflects the increasing recognition of the company by investors

TRANSTHERA-B has been included in the Hang Seng Index series constituents